KES
Search
- Page Path
- HOME > Search
Brief Report
- Diabetes, obesity and metabolism
- Metabolic Consequences of Glucagon-Like Peptide-1 Receptor Agonist Shortage: Deterioration of Glycemic Control in Type 2 Diabetes
- Hun Jee Choe, Michael A. Nauck, Joon Ho Moon
- Endocrinol Metab. 2025;40(1):156-160. Published online November 25, 2024
- DOI: https://doi.org/10.3803/EnM.2024.2150
- 6,645 View
- 121 Download
- 5 Web of Science
- 6 Crossref
-
Abstract
PDF
Supplementary Material
PubReader 
ePub - In the context of a global shortage of glucagon-like peptide-1 (GLP-1) receptor agonists, we assessed the impact of discontinuing dulaglutide on metabolic control in individuals with type 2 diabetes. Our analysis included data from 69 individuals and revealed a significant deterioration in glycemic control following the discontinuation. Specifically, the average hemoglobin A1c level increased from 7.0%±0.9% to 8.1%±1.4% (P<0.001), and fasting glucose levels rose from 129±31 to 156±50 mg/dL (P<0.001) within 3 months after stopping the medication. Alternative treatments such as dipeptidyl peptidase-4 inhibitors and sodium glucose cotransporter- 2 inhibitors were insufficient substitutes, highlighting the essential role of continuous GLP-1 receptor agonist therapy in maintaining metabolic health.
-
Citations
Citations to this article as recorded by
- Assessing the Impact of Glucagon-like Peptide-1 and Glucagon-like Peptide-1/glucose-dependent Insulinotropic Polypeptide Receptor Agonist Shortages on Glycemic Control: A Single Center Study
Christian Dacon, Pramodini Kale-Pradhan, Melissa Lipari
Journal of Pharmacy Practice.2026;[Epub] CrossRef - Metabolic rebound and weight cycling following incretin mimetic drug withdrawal: a cause for concern?
Sarah E. Alexander, Erin J. Howden
Current Opinion in Clinical Nutrition & Metabolic Care.2026; 29(4): 395. CrossRef - Addressing the Shortage of GLP-1 RA and Dual GIP/GLP-1 RA-Based Therapies—A Systematic Review
Velimir Altabas, Zrinka Orlović, Maja Baretić
Diabetology.2025; 6(6): 52. CrossRef - Use of gastric ultrasound to identify GLP-1RA users at high risk of aspiration during surgery
Alessandra T. Ayers, Cindy N. Ho, Nicole Y. Xu, Sergio D. Bergese, Ana Costa, David Kerr, David C. Klonoff
Perioperative Care and Operating Room Management.2025; 41: 100562. CrossRef - Glucagon‑like peptide‑1 receptor agonists in multiple sclerosis: therapeutic promise, challenges, and future directions
Afsaneh Shirani, Olaf Stuve
Expert Opinion on Investigational Drugs.2025; 34(11): 929. CrossRef - Harnessing the gut-brain axis in the treatment of type 2 diabetes mellitus and obesity
Kornela Kotucha, Katarzyna Kapłon, Magdalena Moś, Jakub Fiegler-Rudol, Alina Pietryszyn-Bilińska, Klaudia Dynarowicz, David Aebisher, Rafał Wiench, Aleksandra Kawczyk-Krupka
European Journal of Clinical and Experimental Medicine.2025;[Epub] CrossRef
- Assessing the Impact of Glucagon-like Peptide-1 and Glucagon-like Peptide-1/glucose-dependent Insulinotropic Polypeptide Receptor Agonist Shortages on Glycemic Control: A Single Center Study
First
Prev
